Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Open Access
- 2 May 2011
- journal article
- research article
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 51,p. e2444
- https://doi.org/10.3791/2444
Abstract
Based on their safety profile and ability to induce potent immune responses against infections, subunit vaccines have been used as candidates for a wide variety of pathogens 1-3. Since the mammalian cell system is capable of post-translational modification, thus forming properly folded and glycosylated proteins, recombinant proteins expressed in mammalian cells have shown the greatest potential to maintain high antigenicity and immunogenicity 4-6. Although no new cases of SARS have been reported since 2004, future outbreaks are a constant threat; therefore, the development of vaccines against SARS-CoV is a prudent preventive step and should be carried out. The RBD of SARS-CoV S protein plays important roles in receptor binding and induction of specific neutralizing antibodies against virus infection 7-9. Therefore, in this protocol, we describe novel methods for developing a RBD-based subunit vaccine against SARS. Briefly, the recombinant RBD protein (rRBD) was expressed in culture supernatant of mammalian 293T cells to obtain a correctly folded protein with proper conformation and high immunogenicity 6. The transfection of the recombinant plasmid encoding RBD to the cells was then performed using a calcium phosphate transfection method 6,10 with some modifications. Compared with the lipid transfection method 11,12, this modified calcium phosphate transfection method is cheaper, easier to handle, and has the potential to reach high efficacy once a transfection complex with suitable size and shape is formed 13,14. Finally, a SARS pseudovirus neutralization assay was introduced in the protocol and used to detect the neutralizing activity of sera of mice vaccinated with rRBD protein. This assay is relatively safe, does not involve an infectious SARS-CoV, and can be performed without the requirement of a biosafety-3 laboratory 15. The protocol described here can also be used to design and study recombinant subunit vaccines against other viruses with class I fusion proteins, for example, HIV, respiratory syncytial virus (RSV), Ebola virus, influenza virus, as well as Nipah and Handra viruses. In addition, the methods for generating a pseudovirus and subsequently establishing a pseudovirus neutralization assay can be applied to all these viruses.This publication has 15 references indexed in Scilit:
- Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270Vaccine, 2010
- Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunityVirology, 2009
- Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cellsBiochemical and Biophysical Research Communications, 2009
- Polyethylenimine-Based Transfection Method as a Simple and Effective Way to Produce Recombinant Lentiviral VectorsApplied Biochemistry and Biotechnology, 2008
- Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression systemProtein Expression and Purification, 2005
- Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with ReceptorJournal of Virology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickensVaccine, 2003
- Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfectionGene, 2001
- Theileria annulata : control measures, diagnosis and the potential use of subunit vaccinesRevue Scientifique et Technique de l'OIE, 1990